Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.

Ophthalmology and eye diseases Pub Date : 2012-03-13 Print Date: 2012-01-01 DOI:10.4137/OED.S7264
Roberto Gallego-Pinazo, Rosa Dolz-Marco, Cristina Marín-Lambíes, Manuel Díaz-Llopis
{"title":"Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.","authors":"Roberto Gallego-Pinazo,&nbsp;Rosa Dolz-Marco,&nbsp;Cristina Marín-Lambíes,&nbsp;Manuel Díaz-Llopis","doi":"10.4137/OED.S7264","DOIUrl":null,"url":null,"abstract":"<p><p>Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.</p>","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"4 ","pages":"15-21"},"PeriodicalIF":0.0000,"publicationDate":"2012-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/OED.S7264","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and eye diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/OED.S7264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/1/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

Abstract Image

Abstract Image

雷尼单抗治疗视网膜静脉闭塞后黄斑水肿的安全性和有效性。
黄斑水肿是视网膜静脉阻塞患者视力损害的主要原因。激光光凝或玻璃体注射曲安奈德可获得有限的改善。然而,根据随机临床试验提供的数据,玻璃体内注射雷尼单抗(Lucentis;基因泰克,南旧金山,加州)构成了一个新的有效和安全的选择,管理这些威胁视力的疾病。本综述的目的是总结雷尼单抗治疗视网膜静脉阻塞引起的黄斑水肿的临床证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信